References
1. Holmes, L.B., Human teratogens: update 2010. Birth Defects Res
A Clin Mol Teratol, 2011. 91 (1): p. 1-7.
2. Twining’s Textbook of Fetal Abnormalities , ed. A.M. Coady and
S. Bower. 2014: Elsevier Ltd. 632.
3. Schwarz, E.B., et al., Clinical decision support to promote
safe prescribing to women of reproductive age: a cluster-randomized
trial. J Gen Intern Med, 2012. 27 (7): p. 831-8.
4. Honein, M.A., C.A. Moore, and J.D. Erickson, Can We Ensure the
Safe Use of Known Human Teratogens? Drug Safety, 2004. 27 (14):
p. 1069-1080.
5. Addis, A., S. Sharabi, and M. Bonati, Risk Classification
Systems for Drug Use During Pregnancy. Drug Safety, 2000.23 (3): p. 245-253.
6. Law, R., et al., FDA pregnancy risk categories and the
<em>CPS</em>. Canadian Family Physician, 2010.56 (3): p. 239.
7. Services, U.S.D.o.H.a.H. FDA Pregnancy Categories . [date
accessed 20/12/2019]; Available from:
https://chemm.nlm.nih.gov/pregnancycategories.htm.
8. Mayall, S.J. and A.K. Banerjee, Therapeutic Risk Management of
Medicines . 2014. 448.
9. Administration, F.a.D. Approved Risk Evaluation and Mitigation
Strategies (REMS) . [date accessed 05/06/2019]; Available from:
https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm.
10. Bwire, R., J. Freeman, and F. Houn, Managing the teratogenic
risk of thalidomide and lenalidomide: an industry perspective. Expert
Opin Drug Saf, 2011. 10 (1): p. 3-8.
11. Society, R.P., Medicines Optimisation: Helping patients to
make the most of medicines . 2013.
12. Cutler, S., et al., What does medicines optimisation mean for
pharmacy professionals? Pharmaceutical Journal, 2011.287 (7680): p. 606-607.
13. Widnes, S.F. and J. Schjott, Risk perception regarding drug
use in pregnancy. Am J Obstet Gynecol, 2017. 216 (4): p.
375-378.
14. Collins, J. and D. Bonneh-Barkay, Considerations for
Successful Risk-Minimisation Strategies in the EU. Pharmaceutical
Medicine, 2016. 30 (5): p. 257-261.
15. Gils, C., et al., Perception of drug teratogenicity among
general practitioners and specialists in obstetrics/gynecology: a
regional and national questionnaire-based survey. BMC Pregnancy
Childbirth, 2016. 16 : p. 226.
16. Sanz, E., T. Gomez-Lopez, and M.J. Martinez-Quintas,Perception of teratogenic risk of common medicines. Eur J Obstet
Gynecol Reprod Biol, 2001. 95 (1): p. 127-31.
17. Schwarz, E.B., et al., Prescription of teratogenic medications
in United States ambulatory practices. Am J Med, 2005.118 (11): p. 1240-9.
18. Brandenburg, N.A., et al., Effectiveness of Risk Evaluation
and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide:
Patient Comprehension and Knowledge Retention. Drug Saf, 2017.40 (4): p. 333-341.
19. Hayward, K., et al., Reliable Pregnancy Testing Before
Intravenous Cyclophosphamide: A Quality Improvement Study. Pediatrics,
2016. 138 (6).
20. Leverenz, D.L., et al., Contraception methods used by women
with rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol,
2019. 38 (4): p. 1207-1212.
21. Paton, C., et al., A UK clinical audit addressing the quality
of prescribing of sodium valproate for bipolar disorder in women of
childbearing age. BMJ Open, 2018. 8 (4): p. e020450.
22. Uuskula, A., et al., Compliance with Pregnancy Prevention
Recommendations for Isotretinoin in Estonia in 2012-2016. Drugs Real
World Outcomes, 2018. 5 (2): p. 129-136.
23. Ceulemans, M., et al., Women’s Beliefs About Medicines and
Adherence to Pharmacotherapy in Pregnancy: Opportunities for Community
Pharmacists. Curr Pharm Des, 2019. 25 (5): p. 469-482.
24. Petersen, I., et al., Women's perception of risks of
adverse fetal pregnancy outcomes: a large-scale multinational survey.BMJ Open, 2015. 5 (6): p. e007390.
25. Shrouk, W., D. Steinke, and S. Willis, Risk management of
teratogenic medicines: a systematic review. PROSPERO 2019
CRD42019142944. [date accessed 27/04/2020] Available from:
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019142944
26. Moher, D., et al., Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. PLoS Med, 2009.6 (7): p. e1000097.
27. Dabrowska, A., FDA Risk Evaluation and Mitigation Strategies
(REMS): Description and Effect on Generic Drug Development . 2018.
28. Arnold, N. FDA In Brief: FDA affirms its commitment to
efficient adoption of Risk Evaluation and Mitigation Strategy plans and
to making sure they do not impede generic drug development . 2019
[date accessed 15/10/2019]; Available from:
https://www.fda.gov/news-events/fda-brief/fda-brief-fda-affirms-its-commitment-efficient-adoption-risk-evaluation-and-mitigation-strategy.
29. Hawker, S., et al., Appraising the evidence: reviewing
disparate data systematically. Qual Health Res, 2002. 12 (9):
p. 1284-99.
30. Mitchell, A.A., C.M. Van Bennekom, and C. Louik, A
Pregnancy-Prevention Program in Women of Childbearing Age Receiving
Isotretinoin. New England Journal of Medicine, 1995. 333 (2):
p. 101-106.
31. Cheetham, T.C., et al., A risk management program aimed at
preventing fetal exposure to isotretinoin: retrospective cohort study.J Am Acad Dermatol, 2006. 55 (3): p. 442-8.
32. Steinkellner, A., W. Chen, and S.E. Denison, Adherence to oral
contraception in women on Category X medications. Am J Med, 2010.123 (10): p. 929-934.e1.
33. Rao, R.S., et al., Comparison of alternative survey methods
for sensitive self-reported behaviours in a follow-up study of
isotretinoin. J Epidemiol Biostat, 2000. 5 (2): p. 133-6.
34. Pinheiro, S.P., et al., Concomitant use of isotretinoin and
contraceptives before and after iPledge in the United States.Pharmacoepidemiol Drug Saf, 2013. 22 (12): p. 1251-7.
35. Yazdany, J., et al., Contraceptive counseling and use among
women with systemic lupus erythematosus: a gap in health care quality?Arthritis Care Res (Hoboken), 2011. 63 (3): p. 358-65.
36. Force, R.W., et al., Contraceptive methods and informed
consent among women receiving medications with potential for adverse
fetal effects: a Washington, Wyoming, Alaska, Montana, Idaho (WWAMI)
region study. J Am Board Fam Med, 2012. 25 (5): p. 661-8.
37. Stancil, S.L., et al., Contraceptive Provision to Adolescent
Females Prescribed Teratogenic Medications. Pediatrics, 2016.137 (1).
38. Schwarz, E.B., et al., Counseling about medication-induced
birth defects with clinical decision support in primary care. J Womens
Health (Larchmt), 2013. 22 (10): p. 817-24.
39. Schwarz, E.B., et al., Counseling of female veterans about
risks of medication-induced birth defects. J Gen Intern Med, 2013.28 Suppl 2 : p. S598-603.
40. Schwarz, E.B., et al., Documentation of contraception and
pregnancy when prescribing potentially teratogenic medications for
reproductive-age women. Annals of internal medicine, 2007.147 (6): p. 370-376.
41. Gotlib, D., et al., Guideline adherence for mentally ill
reproductive-aged women on treatment with valproic acid: a retrospective
chart review. The Journal of clinical psychiatry, 2016. 77 (4):
p. 527-534.
42. Landis, E.T., et al., Isotretinoin and oral contraceptive use
in female acne patients varies by physician specialty: analysis of data
from the National Ambulatory Medical Care Survey. J Dermatolog Treat,
2012. 23 (4): p. 272-7.
43. Fritsche, M.D., A.Z. Ables, and H. Bendyk, Opportunities
missed: improving the rate of contraceptive counseling or provision when
prescribing reproductive-aged women potentially teratogenic medications
in a family medicine resident clinic. Contraception, 2011.84 (4): p. 372-6.
44. Schwarz, E.B., et al., Provision of potentially teratogenic
medications to female veterans of childbearing age. Med Care, 2010.48 (9): p. 834-42.
45. Castaneda, C.P., et al., RevAssist: a comprehensive risk
minimization programme for preventing fetal exposure to lenalidomide.Drug Saf, 2008. 31 (9): p. 743-52.
46. Bhakta, J., J. Bainbridge, and L. Borgelt, Teratogenic
medications and concurrent contraceptive use in women of childbearing
ability with epilepsy. Epilepsy Behav, 2015. 52 (Pt A): p.
212-7.
47. Brinker, A., C. Kornegay, and P. Nourjah, Trends in adherence
to a revised risk management program designed to decrease or eliminate
isotretinoin-exposed pregnancies: evaluation of the accutane SMART
program. Arch Dermatol, 2005. 141 (5): p. 563-9.
48. Goyal, M.K., et al., Underuse of pregnancy testing for women
prescribed teratogenic medications in the emergency department. Acad
Emerg Med, 2015. 22 (2): p. 192-6.
49. Mody, S.K., et al., Using the electronic medical record to
assess contraception usage among women taking category D or X
medications. Birth Defects Res A Clin Mol Teratol, 2015.103 (10): p. 887-91.
50. Mody, S.K., et al., Using the electronic medical record to
refer women taking category D or X medications for teratogen and
contraceptive counseling. Birth Defects Res A Clin Mol Teratol, 2015.103 (7): p. 644-7.
51. DiPietro Mager, N., C. Mills, and A. Snelling, Utility of
reproductive life plans in identification of potentially teratogenic
medication use: A pilot study. Birth, 2018. 45 (1): p. 50-54.
52. Ferguson, S., et al., Who receives contraception counseling
when starting new lupus medications? The potential roles of race,
ethnicity, disease activity, and quality of communication. Lupus, 2016.25 (1): p. 12-7.
53. Werner, C.A., et al., Women’s experiences with isotretinoin
risk reduction counseling. JAMA Dermatol, 2014. 150 (4): p.
366-71.
54. Wieck, A., et al., A survey of antiepileptic prescribing to
women of childbearing potential in psychiatry. Arch Womens Ment Health,
2007. 10 (2): p. 83-5.
55. Valle, J., et al., Contraceptive use by women receiving
chemotherapy for breast cancer. The Breast, 1998. 7 (3): p.
143-149.
56. Bell, G.S., et al., Information recalled by women taking
anti-epileptic drugs for epilepsy: a questionnaire study. Epilepsy Res,
2002. 52 (2): p. 139-46.
57. James, L., et al., Informing patients of the teratogenic
potential of mood stabilizing drugs: a case note review of the practice
of psychiatrists. J Psychopharmacol, 2007. 21 (8): p. 815-9.
58. Langan, J., A. Perry, and M. Oto, Teratogenic risk and
contraceptive counselling in psychiatric practice: analysis of
anticonvulsant therapy. BMC Psychiatry, 2013. 13 : p. 234.
59. Chave, T.A., A.Y. Finlay, and A.G. Knight, Thalidomide usage
in Wales: the need to follow guidelines. Br J Dermatol, 2001.144 (2): p. 310-5.
60. Martin, U., et al., Use of ACE inhibitors and ARBs in
hypertensive women of childbearing age. J Clin Pharm Ther, 2008.33 (5): p. 507-11.
61. Atturu, H. and A. Odelola, Valproate Prescribing in Women of
Childbearing Age: An Audit of Clinical Practice. Advances in
Psychiatry, 2015. 2015 : p. 6.
62. Shilalukey, K., et al., Counseling sexually active teenagers
treated with potential human teratogens. J Adolesc Health, 1997.21 (3): p. 143-6.
63. Hogan, D.J., L.M. Strand, and P.R. Lane, Isotretinoin therapy
for acne: a population-based study. Cmaj, 1988. 138 (1): p.
47-50.
64. Boucher, N. and L. Beaulac-Baillargeon, Pregnancy prevention
among women taking isotretinoin: failure to comply with the
recommendations. Canadian family physician Medecin de famille canadien,
2006. 52 (3): p. 338-339.
65. Ruiter, R., et al., Concomitant use of contraceptives and
potentially teratogenic medicinal products–results from a study using
pharmacy dispensing data in the Netherlands. Reprod Sci, 2012.19 (9): p. 987-94.
66. Teichert, M., et al., Isotretinoin use and compliance with the
Dutch Pregnancy Prevention Programme: a retrospective cohort study in
females of reproductive age using pharmacy dispensing data. Drug Saf,
2010. 33 (4): p. 315-26.
67. Crijns, H.J., et al., Prescriptive contraceptive use among
isotretinoin users in the Netherlands in comparison with non-users: a
drug utilisation study. Pharmacoepidemiol Drug Saf, 2012.21 (10): p. 1060-6.
68. Bosak, M., K. Cyranka, and A. Slowik, Hormonal contraception
in patients with epilepsy. Ginekol Pol, 2019. 90 (2): p. 61-65.
69. Banas, T., et al., Use of contraception by women treated with
leflunomide due to rheumatic arthritis. J Obstet Gynaecol, 2014.34 (1): p. 60-4.
70. Mulryan, D., et al., Awareness and documentation of the
teratogenic effects of valproate among women of child-bearing
potential. BJPsych Bull, 2018. 42 (6): p. 233-237.
71. Lelubre, M., et al., Evaluation of compliance with
isotretinoin PPP recommendations and exploration of reasons for
non-compliance: Survey among French-speaking health care professionals
and patients in Belgium. Pharmacoepidemiol Drug Saf, 2018.27 (6): p. 668-673.
72. Raguideau, F., et al., Compliance with pregnancy prevention
plan recommendations in 8672 French women of childbearing potential
exposed to acitretin. Pharmacoepidemiol Drug Saf, 2015. 24 (5):
p. 526-33.
73. Entezari-Maleki, T., et al., Evaluation and monitoring of
isotretinoin use in Iran. Arch Iran Med, 2012. 15 (7): p.
409-12.
74. Ozyurt, S. and A.F. Kaptanoglu, Systemic Isotretinoin
Treatment and Pregnancy: A Longitudinal Cohort Study from Turkey. The
Eurasian journal of medicine, 2015. 47 (3): p. 179-183.
75. Tsur, L., E. Kozer, and M. Berkovitch, The effect of drug
consultation center guidance on contraceptive use among women using
isotretinoin: a randomized, controlled study. J Womens Health
(Larchmt), 2008. 17 (4): p. 579-84.
76. Chang, A.Y., et al., Motivations of women in Uganda living
with rheumatic heart disease: A mixed methods study of experiences in
stigma, childbearing, anticoagulation, and contraception. PLoS One,
2018. 13 (3): p. e0194030.
77. Algoblan, S., et al., Women's experiences regarding
isotretinoin risk reduction counseling in Riyadh. Journal of
Dermatology and Dermatologic Surgery, 2019. 23 (1): p. 13-15.
78. Schwarz, E.B., et al., Promoting safe prescribing in primary
care with a contraceptive vital sign: a cluster-randomized controlled
trial. Ann Fam Med, 2012. 10 (6): p. 516-22.
79. Lupattelli, A., et al., Health literacy and its association
with perception of teratogenic risks and health behavior during
pregnancy. Patient Educ Couns, 2014. 96 (2): p. 171-8.
80. Nordeng, H., E. Ystrom, and A. Einarson, Perception of risk
regarding the use of medications and other exposures during pregnancy.Eur J Clin Pharmacol, 2010. 66 (2): p. 207-14.
81. Damase-Michel, C., et al., Perception of teratogenic and
foetotoxic risk by health professionals: a survey in Midi-Pyrenees
area. Pharmacy practice, 2008. 6 (1): p. 15-19.
82. Pons Eda, S., S. Pizzol Tda, and D.R. Knauth, Perceptions by
pregnant and childbearing-age women in southern Brazil towards
teratogenic risk from medicines and radiotherapy. Cad Saude Publica,
2014. 30 (9): p. 1965-76.
83. Leiderman, D.B., Risk management of drug products and the U.S.
Food and Drug Administration: evolution and context. Drug Alcohol
Depend, 2009. 105 Suppl 1 : p. S9-S13.
84. Crijns, H.J., et al., Compliance with pregnancy prevention
programmes of isotretinoin in Europe: a systematic review. Br J
Dermatol, 2011. 164 (2): p. 238-44.
85. Bérard, A., et al., Isotretinoin, pregnancies, abortions and
birth defects: a population-based perspective. British Journal of
Clinical Pharmacology, 2007. 63 (2): p. 196-205.
86. Althubaiti, A., Information bias in health research:
definition, pitfalls, and adjustment methods. Journal of
multidisciplinary healthcare, 2016. 9 : p. 211-217.
87. Schmier, J.K. and M.T. Halpern, Patient recall and recall bias
of health state and health status. Expert Rev Pharmacoecon Outcomes
Res, 2004. 4 (2): p. 159-63.
88. Social Desirability Bias , in Wiley International
Encyclopedia of Marketing .
89. Herrett, E., et al., Data Resource Profile: Clinical Practice
Research Datalink (CPRD). International Journal of Epidemiology, 2015.44 (3): p. 827-836.
90. Zozus, M.N., et al., Factors Affecting Accuracy of Data
Abstracted from Medical Records. PLOS ONE, 2015. 10 (10): p.
e0138649.
91. Freeman, J., et al., Teratogenic Drugs and Risk Management: An
Implementation Assessment. Ther Innov Regul Sci, 2014. 48 (4):
p. 420-427.
92. Shorten, A. and J. Smith, Mixed methods research: expanding
the evidence base. Evidence Based Nursing, 2017. 20 (3): p.
74-75.
93. Tisnado, D.M., et al., What Is the Concordance between the
Medical Record and Patient Self-Report as Data Sources for Ambulatory
Care? Medical Care, 2006. 44 (2): p. 132-140.
94. Peters, E., et al., Numeracy Skill And The Communication,
Comprehension, And Use Of Risk-Benefit Information. Health Affairs,
2007. 26 (3): p. 741-748.
95. Rothman, R.L., et al., Perspective: the role of numeracy in
health care. Journal of health communication, 2008. 13 (6): p.
583-595.
96. Pons, E.d.S., et al., Analysis of agreement between Visual
Analogue Scales (VAS) and numerical questions to assess perception of
teratogenic risks in treatment with drugs and radiotherapy in women.Revista Brasileira de Saúde Materno Infantil, 2014. 14 : p.
393-399.
97. Harland, N.J., M.J. Dawkin, and D. Martin, Relative utility of
a visual analogue scale vs a six-point Likert scale in the measurement
of global subject outcome in patients with low back pain receiving
physiotherapy. Physiotherapy, 2015. 101 (1): p. 50-54.
98. Twigg, M.J., A. Lupattelli, and H. Nordeng, Women’s beliefs
about medication use during their pregnancy: a UK perspective.International Journal of Clinical Pharmacy, 2016. 38 (4): p.
968-976.
99. Polifka, J.E., E.M. Faustman, and N. Neil, Weighing the risks
and the benefits: A call for the empirical assessment of perceived
teratogenic risk. Reproductive Toxicology, 1997. 11 (4): p.
633-640.
100. Lennon, S.L., Risk perception in pregnancy: a concept
analysis. Journal of Advanced Nursing, 2016. 72 (9): p.
2016-2029.
101. Widnes, S.F., et al., Teratogenic risk perception and
confidence in use of medicines in pairs of pregnant women and general
practitioners based on patient information leaflets. Drug Saf, 2013.36 (6): p. 481-9.
102. Schwarz, E.B., et al., Perspectives of primary care
clinicians on teratogenic risk counseling. Birth Defects Res A Clin Mol
Teratol, 2009. 85 (10): p. 858-63.
Table 1. Specific risk minimisation measures reported in the included
papers.